Clinical trial
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
NCT06228339 is registered in ClinicalTrials.gov with International Bio service as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets and Reference Product (Xatral® XL 10 mg) in Healthy Thai Male Volunteers Under Fed Conditions
- Lead sponsor
- International Bio service
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- March 9, 2024
- Completion date
- March 21, 2024
- Enrollment
- 44 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
healthy volunteer